Guidant, Boston Scientific Agree To Settle Patent Suits, Exchange Licenses
This article was originally published in The Gray Sheet
Executive Summary
A comprehensive patent settlement between Boston Scientific and Guidant, announced May 17, covers all current patent litigation pending between the two companies, including coronary stent systems and dilatation catheters. The deal also includes cross licensing of "certain patents" related to the litigation.
You may also be interested in...
Boston Scientific Express Stent Potentially Threatened By Medinol Lawsuit
Boston Scientific's strategy to rely on its internally developed Express coronary stent platform as a viable alternative to a troubled relationship with stent partner Medinol may be jeopardized by the Israeli firm's April 5 lawsuit alleging that the Express R&D initiative constituted breach of contract by Boston Scientific.
Boston Scientific Express Stent Potentially Threatened By Medinol Lawsuit
Boston Scientific's strategy to rely on its internally developed Express coronary stent platform as a viable alternative to a troubled relationship with stent partner Medinol may be jeopardized by the Israeli firm's April 5 lawsuit alleging that the Express R&D initiative constituted breach of contract by Boston Scientific.
Guidant, J&J Agree To Arbitrate Suits, Exchange Licenses And Technology
Guidant will evaluate in preclinical studies electronic field stimulation (EFS) technology gained through an agreement with Johnson & Johnson before deciding whether to incorporate it into its biventricular pacing device to treat congestive heart failure, the firm says.